|
MED4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.53380000051429E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.63060000000415E-05 |
| Normal-vs-Stage2 |
1.78949999999345E-05 |
| Normal-vs-Stage3 |
4.60560000004051E-06 |
| Normal-vs-Stage4 |
1.79199999950086E-07 |
| Stage1-vs-Stage2 |
1.239820E-01 |
| Stage1-vs-Stage3 |
1.956560E-01 |
| Stage1-vs-Stage4 |
7.832200E-02 |
| Stage2-vs-Stage3 |
6.258600E-01 |
| Stage2-vs-Stage4 |
8.146800E-01 |
| Stage3-vs-Stage4 |
7.328600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.21310000045227E-07 |
| Normal-vs-AfricanAmerican |
1.714360E-02 |
| Normal-vs-Asian |
6.582500E-03 |
| Caucasian-vs-AfricanAmerican |
3.223800E-01 |
| Caucasian-vs-Asian |
7.960200E-02 |
| AfricanAmerican-vs-Asian |
7.878200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.90942999999111E-05 |
| Normal-vs-Female |
1.03979999999115E-06 |
| Male-vs-Female |
8.149000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.355190E-04 |
| Normal-vs-Age(41-60Yrs) |
3.53789999996135E-06 |
| Normal-vs-Age(61-80Yrs) |
3.38029999547018E-08 |
| Normal-vs-Age(81-100Yrs) |
2.195300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.554000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.187910E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.000400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.340200E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.212200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.492600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.205800E-01 |
| Classical-VS-Follicular |
1.151040E-01 |
| Classical-VS-Other |
8.949400E-01 |
| Classical-VS-Normal |
4.00620000000629E-05 |
| Tall-VS-Follicular |
5.136400E-01 |
| Tall-VS-Other |
9.604200E-01 |
| Tall-VS-Normal |
1.903240E-03 |
| Follicular-VS-Other |
6.978600E-01 |
| Follicular-VS-Normal |
2.45639999999492E-05 |
| Other-VS-Normal |
8.320000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.31729999633501E-08 |
| Normal-vs-N1 |
9.51930000000489E-05 |
| N0-vs-N1 |
7.012200E-01 |
|
|
